Pharmacological Effects of PARP Inhibitors on Cancer and other Diseases

Author(s): Luis M. Guaman-Ortiz, Vincenzo Giansanti, Francesca Dona, A. Ivana Scovassi

Journal Name: Current Enzyme Inhibition

Volume 7 , Issue 4 , 2011

Become EABM
Become Reviewer
Call for Editor


Poly(ADP-ribosylation), a post-translational modification of proteins involved in DNA repair, replication, transcription and cell death, consists in the conversion of ß-NAD+ into ADP-ribose, and the further formation of polymers of variable length and structure bound to nuclear protein acceptors. Polymer synthesis and degradation are performed respectively by poly(ADP-ribose) polymerase (PARP) and poly(ADP-ribose) glycohydrolase (PARG) enzymes. Poly(ADP-ribosylation) represents an emergency reaction to DNA damage; however, PARP overactivation promotes NAD depletion and consequent necrosis, thus exerting a noxious function in many circumstances. The search for chemical compounds able to inhibit poly(ADP-ribosylation) allowed the discovery of new molecules and potent derivatives. Pharmacological inhibition of PARP enzymes is able to reverse the deleterious NAD consumption, thus having a protective role towards many pathological conditions. Of note, the combined treatment of tumors with PARP inhibitors and anticancer drugs has been shown to have a beneficial effect in anticancer therapy. On the whole, pharmacological inactivation of poly(ADP-ribosylation) represents a novel therapeutic strategy to limit cellular injury and to improve the prognosis of a variety of diseases.

Keywords: Cancer, cell death, DNA repair, inflammation, neurodegenerative diseases, PARG inhibitors, PARP inhibitors, poly(ADP-ribosylation), tankyrases, diabetes

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2011
Published on: 03 April, 2012
Page: [244 - 258]
Pages: 15
DOI: 10.2174/157340811799860524
Price: $65

Article Metrics

PDF: 10